TY - T1的抗凝治疗急性缺血性中风后的时机及其关系的风险颅内出血(p1.3 - 003) JF -神经学乔-神经学六世- 92 - 15补充SP - p1.3 - 003 AU -乌斯曼Shehzad盟卡米尔Stefanowski AU -瑞恩·琼斯盟亚历克斯收税官非盟-林赛St首页emke盟- Lev Bangiyev AU -大卫程序非盟-迈克尔·圭多Y1 - 2019/04/09 UR - //www.ez-admanager.com/content/92/15_supplement/p1.3 - 003. -抽象N2 -目的:检查出血性转化缺血性中风的风险基础房颤患者中风体积和时间的基础上开始抗凝治疗(AC)。背景:二次中风的主要预防基础房颤抗凝治疗的设置。然而,大量急性缺血性中风后,对出血性转换被认为超过它的好处恢复或开始抗凝治疗经常导致严重的延误治疗。缺乏数据指导神经学家充分评估抗凝治疗的风险效益比在此设置。目前,在临床实践中有一个变化和大多数专家意见建议开始抗凝治疗中风的14天内。设计/方法:我们进行了回顾性图表分析的患者解除石溪大学医院在日历年2013 - 2017年的诊断缺血性中风和心房纤维性颤动。病人开始DOACs以及维生素K拮抗剂都包括在内。我们评估了脑梗塞体积通过手动选择hyperintense病变扩散加权磁共振图像序列其次是半自动卷分割和测量使用齐墩果球体体积分析软件3.0版本。结果:第一个200图表,112名患者合格的研究。抗凝治疗开始67例中风后的前2天,17天AC发起了3 - 5、6 - 7天,10天7 - 14,和11后14天。中风卷从0.09毫升到160.33毫升不等。没有出血性转换症状的发生率和没有患者复发性中风而等待开始AC.Conclusions:首先分析112例显示没有增加出血的风险交流开始不管中风后体积或起始日。披露:Shehzad博士没有披露。Stefanowski没有披露博士。 Dr. Jones has nothing to disclose. Dr. Gauger has nothing to disclose. Dr. Stemke has nothing to disclose. Dr. Bangiyev has nothing to disclose. Dr. Fiorella has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Medtronic, Codman, Sequent Medical, Microvention. Dr. Fiorella has received compensation for serving on the Board of Directors of Vascular Simulations . Dr. Fiorella has received royalty, license fees, or contractual rights payments from Codman/JnJ. Dr. Fiorella has received research support from Siemens, Penumbra, Sequent Medical, Microvention. Dr. Guido has nothing to disclose. ER -